RxDoctor Payments Data

Richard Dewey, MD

Neurology · Boca Raton, FLNPI 1104358878

Payments from drug & device makers

$48,564in general payments, 2019–2025

Across 223 payments — averaging $217.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$15K
  • Medtronic$15K
  • Amneal Pharmaceuticals LLC$8K
  • Sage Therapeutics, LLC$2K
  • Biogen$2K
  • H. Lundbeck A S$2K
  • plus $4K from 13 others

What the payments were for

  • Consulting fees$1,0502%
  • Speaking & faculty fees$5,81012%
  • Grants$30,00064%
  • Travel & lodging$2,8246%
  • Food & beverage$7,05115%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,564 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$252,353
Medicare patients
314
Services billed
10,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate110$658,423
RytaryCarbidopa/Levodopa515$566,379
Austedo XrDeutetrabenazine20$265,481
GocovriAmantadine Hcl39$231,848
InbrijaLevodopa28$120,506
OngentysOpicapone86$103,089
NourianzIstradefylline11$40,133
XadagoSafinamide Mesylate15$37,470
Carbidopa-LevodopaCarbidopa/Levodopa529$22,823
BotoxOnabotulinumtoxina23$20,332
NeuproRotigotine11$17,499
CrexontCarbidopa/Levodopa16$12,114
Rivastigmine38$9,886
XeominIncobotulinumtoxina14$9,092
Galantamine ErGalantamine Hbr74$7,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$928$658,423110 claims
Amneal Pharmaceuticals LLCRytary, Crexont$7,815$578,493531 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$563$265,48120 claims
MDD US Operations, LLCGocovri$334$231,84839 claims
Acorda Therapeutics, IncInbrija$361$120,50628 claims
Neurocrine Biosciences, Inc.Ongentys$706$103,08986 claims
Kyowa Kirin, Inc.Nourianz$533$40,13311 claims
AbbVieBotox$829$20,33223 claims
Almatica Pharma LLCSertraline Hcl$39$91088 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →